The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer

Recent Advances in Medicinal Chemistry

Volume: 2

DOI: 10.2174/9781681081717115020008
eISBN: 978-1-68108-171-7, 2015
ISBN: 978-1-68108-172-4
ISSN: 2452-3682 (Print)
ISSN: 2215-0722 (Online)

Indexed in: EBSCO.

Recent Advances in Medicinal Chemistry is a book series focused on leading-edge research on developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, ...

[view complete introduction]

US $
	30

*(Excluding Mailing and Handling)

Back

The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer

Pp. 144-155 (12)

Giuseppe Pasqualetti, Sergio Ricci, Valeria Calsolaro, Sara Tognini, Antonio Polini and Fabio Monzani

Abstract

Tyrosine kinase receptors have been shown to play an important role in epithelial thyroid tumor growth and angiogenesis. Thyroid cancers commonly present oncogene mutations involved in MAPK kinase pathway like BRAF and RET; they are also frequently dependent from VEGF stimuli. Preliminary clinical experiences suggest a promising role of sunitinib (a tyrosine kinase inhibitor) for the treatment of advanced thyroid cancers. This chapter deals with the available data on the effect of sunitinib in the treatment of metastatic, radioiodine refractory thyroid cancers.

Keywords:

AKT/PI3K pathways, follicular thyroid cancer, hypothyroidism, levothyroxine, macrocytosis, MAPK kinase, metastasis, neoangiogenesis, papillary thyroid cancer, PDGFR-ß, PDGFR-α, radioactive iodine, refractory DTC, RET, RET/PTC, sunitinib, Thyroid cancer, TSH suppressive, tyrosin-kinase inhibitor, VEGF, VEGFR.

Affiliation:

Geriatrics Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Via Roma 67, 56126 - Pisa, Italy.